These results demonstrated that IGF1R inhibitor linsitinib combined with PTK2 inhibitor defactinib prominently suppressed BACH1-induced HCC metastasis, providing a promising combination strategy for HCC therapy. Here, PTK2 is linked to hepatocellular carcinoma.